Fat Absorption and Metabolism After Roux-en-Y Gastric Bypass (FAT-BAR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hvidovre, Denmark, 2650
- Hvidovre Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria, RYGB
- Age > 18 years
- RYGB > 12 months prior to inclusion
- Weight stable (± 3 kg during the last month)
- HbA1c < 48 mmol/mol before surgery, and no history of diabetes
- HbA1c < 48 mmol/mol and fasting plasma glucose < 6.1 mmol/l at inclusion
Inclusion criteria, CON
- Age > 18 years
- No former bariatric surgery
- Weight stable (± 3 kg during the last month)
- HbA1c < 48 mmol/mol, fasting plasma glucose < 6.1, and no history of diabetes
Exclusion criteria
- Thyrotoxicosis or inadequately treated hypothyreosis
- Haemoglobin < 6.5 mmol/l at inclusion
- Pregnancy (pregnancy test in fertile woman before enrolment) or breast feeding
- Medication affecting the planned examinations which cannot be paused during the study period.
- Adherence to extreme diets with excessively high or low contributions from certain macronutrients (e.g. ketogenic diet)
- Complications restricting eating behavior (e.g. postprandial hypoglycemia, vomiting or strictures)
- MR contraindications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Roux-en-Y gastric bypass operated participants
Roux-en-Y gastric bypass operated participants in weight stable phase > 1 year from surgery
|
Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
Dual energy X-ray Absorptiometry scan of whole-body fat
Magnetic resonance spectroscopy of liver fat content
4-day feces collection
|
|
Experimental: Control participants
Age, sex, and BMI-matched un-operated participants.
|
Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
Dual energy X-ray Absorptiometry scan of whole-body fat
Magnetic resonance spectroscopy of liver fat content
4-day feces collection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the curve of plasma triacylglycerol
Time Frame: 6 hours
|
During a high-fat liquid mixed meal test
|
6 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery of oral stable triacylglycerol isotope tracer in feces
Time Frame: 4 days
|
An oral stable triacylglycerol isotope tracer will be administered during a high-fat liquid mixed meal test.
Feces will be collected the following 4 days to determine the recovery of the tracer in feces.
|
4 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- FAT-BAR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.